Concepedia

Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma

Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A. Adjei, Jeffrey N. Miner, Dominik Mumberg, Karl Ziegelbauer, Arne Scholz

Neoplasia · 2013 · 55 citations · 27 references

DOIFull text

Open access

References

27

Global cancer statistics

Ahmedin Jemal, Freddie Bray · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 12.8K citations · Full text

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

, , +12

Sorafenib in Advanced Hepatocellular Carcinoma

재연 정 · 2008 · 5.6K citations

, , +5

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

, , +12